Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMAGINE: Immunoscore vs TNM in Stage III Colon Cancer
NCT04488159Phase 3Withdrawn
- Sponsor
- Johannes Längle
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colon cancer (2 arms), sponsored by Johannes Längle. Primary endpoint: Disease-free survival at 3 years. Planned start Dec 2024; status: withdrawn.
02
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04488159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488159.